A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Proprietary Information - Exploratory (Non-Confirmatory) Trial

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00397683

Enrollment

Registered

2006-11-09

Start date

2006-10-31

Completion date

2007-04-30

Last updated

2015-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The purpose of this study is to test MK0822 on disease activity in patients with osteoarthritis in the knee. Disease modifying activity of MK0822 will be assessed by measurements of knee cartilage using Magnetic Resonance Imaging (MRI) of the knee. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Interventions

DRUGMK0822

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with symptomatic knee osteoarthritis for at least 6 months based on clinical and radiographic criteria * Patients should be in general good health and must have a certain level of knee pain or be taking pain medicines on most days * Specific radiographic (X-ray) and MRI features must also be satisfied

Exclusion criteria

* Non-osteoarthritic causes of knee pain * Ineligibility to undergo MRI of the knee due to patient tolerability or safety reasons * Previous septic arthritis, tibial osteotomy or knee replacement in both knees * Acute injury of knee ligaments or meniscus in past 2 years * Knee arthroscopy in past 12 months * Anticipated arthroscopy or surgery in next 18 months * Use of intra-articular injections of hyaluronan (e.g. Hyalgan (TM), Synvisc (TM), Orthovisc (TM)) in past 6 months, or injections of glucocorticoids (e.g. Kenalog (TM), Aristospan (TM), Depo-Medrol (TM)) in past 3 months or anticipated knee injections during the study * Glucosamine or chondroitin sulfate are allowable if they are at a stable dose for past 3 months and will continue at that dose during the study * Other

Design outcomes

Primary

Measure	Time frame
Proprietary Information - Exploratory (Non-Confirmatory) Trial	—

Secondary

Measure	Time frame
Proprietary Information - Exploratory (Non-Confirmatory) Trial	—

Countries

Chile, Colombia, Mexico, Poland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026